On February 5, 2026, the administration launched TrumpRx, an online platform designed to help cash‑paying patients access prescription drugs at discounted prices. TrumpRx does not dispense medications directly but connects consumers to manufacturer-sponsored direct‑to‑consumer sites, participating pharmacies, and printable coupons. Although discount prices on TrumpRx are lower than list prices, insured patients may still pay less via traditional copays. At present, purchases made through the platform do not count toward insurance deductibles or out‑of‑pocket maximums, which could increase long‑term OOP responsibility. Discussions are reportedly underway to explore integrating TrumpRx purchases with insurance benefit accumulators.
More than half of the drugs currently listed have available generics or biosimilars, which may limit potential savings on those products. As of launch, the platform features 43 medications from AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer – the first manufacturers to agree to the administration’s most‑favored‑nation (MFN) pricing initiative. The administration has indicated more manufacturers and medications will be added over time.
